Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
Park JS, Gazzaniga FS, Wu M, Luthens AK, Gillis J, Zheng W, LaFleur MW, Johnson SB, Morad G, Park EM, Zhou Y, Watowich SS, Wargo JA, Freeman GJ, Kasper DL, Sharpe AH.
Park JS, et al.
Nature. 2023 May;617(7960):377-385. doi: 10.1038/s41586-023-06026-3. Epub 2023 May 3.
Nature. 2023.
PMID: 37138075
Free PMC article.